OEL Fastrac Catalog

Castor oil is indicated for over-the-counter (OTC) oral use as a laxative, and it is indicated for use in colonic evacuation to empty bowel prior to surgery or radiologic, proctoscopic or sigmoidoscopic procedures, when thorough evacuation is essential. It is also is also added in commercial cosmetic, hair and skincare products. Castor oil is a mix of triglycerides consisting mainly of ricinolein, linoleic acid, oleic acid, palmitic acid, stearic acid, dihydroxystearic acid and traces of other fatty acids. The main pharmacodynamic effects of castor oil are mediated by ricinoleic acid, a hydroxylated fatty acid that is released from castor oil by intestinal lipases. It was thought that ricinoleic acid acts as an anionic surfactant that reduces net absorption of fluid and electrolytes and stimulates intestinal peristalsis. However, a recent study suggests that ricinoleic acid interacts with EP3 prostanoid receptors on intestinal and uterine smooth cells. Ricinoleic acid promotes laxation and uterus contraction.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API).

Please note: Due to the complexity and amount of studies regarding this compound—a Natural Health Product—increased cost is charged.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL monograph for Castor Oil, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.